Services Overview

We act as your agent, representative, interim or mentor/coach. We can set up your company in Japan. We are dedicated to making your commercial success real!

We supply the market intelligence you need to be successful in Japan!

We connect you with the right Japanese companies within Biopharma, ATMP, CGT, Regenerative Medicine, Pharmaceuticals, Combination Devices, IVD’s, Universities and distributors. The right mix you need among: Trade Shows, KOLs, customers, partners, distributors . . .

A handshake under the Rising Sun of Japan.

Biosector = Commercialization in Japan

Preparation and reports – What you need to know!

We produce your feasibility studies and all other types of reports that you need to unlock your commercial pathway into Japan’s Pharmaceutical Industry. We help pave every step of your commercialization process.

Download for free:

You need: fast, accurate and actionable reports, feasibility studies, target lists and analysis to be able to draw up the best strategies.

We supply: just that!

By partnering with Biosector, you get the upper hand!

Market Entry: Seamless Integration and Strategic Positioning

Your success in Japan requires the following keys:

  1. Budget
  2. Cultural competence
  3. Clear goals
  4. Strategic approach
  5. Feet on the ground
  6. Long term mindset
  7. Patience
  8. Consistency


We make sure you are moving as fast as possible and that your expectations are aligned with those of your future clients and partners’ in Japan.

Market Expansion: Optimizing Your New Commercial Opportunities and Accelerating Growth

Expanding your footprint in Japan is crucial. Accelerating your growth successfully equals long-term success. You need competence and excellence: we supply! You need to optimize your new avenues for growth – we support you! We assist you in making sure of your new market segments and their strategies.

Leveraging your opportunities through our extensive industry connections is a valuable shortcut.

With Biosector, you have the advantage that only comes with exceptional professionals. Every step of the way.

About Stefan Sandström 

CEO of Biosector Ltd. Residence

Residence: Based in Metropolitan Tokyo since 2007.

Unique Perspective: Science and business.

Education: Medicine and chemical engineering.

Leadership: Successfully led multiple industrial companies as CEO.

Accreditations: Accredited business consultant via  German RKW.

Collaborations: Japanese partner to notable entities:  SPECTARIS and Kalms Consulting.

Recognitions: Appointed as an expert on conducting business in Japan by the EU-Japan Centre for Industrial Cooperation.

Track Record: Three decades of experience in international and cross-border business development, achieving first sales.

Passion: Kendo (martial art) with the rank of 6 dan.

Testimonials/Cases

Dan Spacie

CEO of MAP Patient Access, UK

”I have worked with Stefan Sandström outside of Biosector for over a year and will continue to work with him in Biosector. This is an exceptionally highly skilled partner, walking the extra mile and having made all the difference for building our traction in Japan.”

Anne-Kathrin Schmalz

Senior Manager Foreign Trade and Export Promotion

”Mr Sandström delivered an amazing seminar for our members in Sep 2021. He combined extensive specialist knowledge of the Japanese bio and laboratory market and how to bridge cultural differences. ”

Tony White

“Biosector’s business intelligence has helped me identify investment opportunities I would never have discovered. They deliver incisive analysis applying the Pareto Principle, allowing me to make fast decisions and save huge amounts of time. A great help for guiding the next steps forward.” – Tony White, founder of BioPhorum and angel investor

Blog

Illustration of Stefan Sandström beside a Shionogi sign outside the former JT Pharma research centre in Takatsuki, Japan.
Shionogi’s planned USD 2 billion acquisition of IntraBio gives you a reason to revisit your Japan partner shortlist. Before you approach a potential partner, ask what your programme adds, which rights you can offer and who owns the decision. A credible commercial proposition makes the conversation worth having.
Illustration of Sweden’s researcher-owned innovation model: a scientist holds her invention while entrepreneurs and mentors help develop it into a business.
What makes researchers choose a university’s support when they own their inventions? Explore how KTH combines researcher ownership with business coaching, venture builders and early investment to help turn discoveries into companies. Listen to bioSector’s first share-worthy AI-generated podcast, created with Google NotebookLM, or read the edited transcript.
生存している神経細胞でも機能異常が生じ得ることを示す、神経ネットワークと電気生理学的・カルシウムシグナル解析の概念図
生存率だけでは捉えきれない神経毒性を、光学的電気生理、HD-MEA、ハイコンテントイメージング、ヒトiPSC由来神経系、共培養モデルを用いて多面的に評価。急性・遅発性神経毒性、神経炎症、機能・構造変化を捉えるin vitro神経毒性評価について解説します。
5つの候補化合物を神経毒性リスクに基づいて比較し、4つをNO GO、1つをGOと判断する創薬意思決定の概念図
創薬初期に神経毒性リスクを捉え、候補化合物の比較やgo/no-go判断に活かすための考え方を解説。Cellectriconのin vitro神経毒性評価、急性・遅発性毒性、神経炎症、ヒトiPSC由来モデルを用いた早期リスク低減について紹介します。
Stefan Sandström presenting Daiichi Sankyo’s Shinagawa R&D Center in Tokyo.
I often hear that Daiichi Sankyo is only available as an ADC partner. This, however, is far from a nuanced truth. So, I put together this analysis using mainly Daiichi Sankyo’s own source material. My purpose is to help you read the company as it is […]
Stefan Sandstrom by Astellas HQ in Nihonbashi
The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan 2026, CSP2026, is built around a clear transition. Astellas wants to maximise revenue from today’s strategic brands while accelerating the pipeline assets expected to drive growth from FY2029. For your […]

Please feel warmly welcome to contact us:

email: info@biosector.jp
phone: +81 80-3404-8431

Address: Yokohama Landmark Tower, 20th Floor, 2-2-1 Minatomirai, Nishi-ku, 〒220-8120,

Yokohama, JAPAN

Deliveries: Kosugaya 1-20-6-202, Sakae-ku, 〒247-0007, Yokohama, JAPAN